IDperform: Predicting the Efficacy of Resistance Exercise Training for Improving Endurance Performance

Sponsor
Inland Norway University of Applied Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT04637178
Collaborator
(none)
25
1
2
3.4
7.5

Study Details

Study Description

Brief Summary

The overall objective of the study is to identify molecular determinants of the efficacy of resistance training for improving endruance performance in elite cyclists

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Resistance training
  • Behavioral: Endurance training (habitual)
N/A

Detailed Description

For elite endurance athletes, the addition of resistance training to habitual endurance training routines generally leads to improved endurance performance. However, this is not always the case, with several individuals failing to respond in the expected manner. This inter-individual variation is likely associated with inherent cellular and molecular charateristics of skeletal muscle. Indeed, responses to resistance training seem to be associated with muscle biological characteristics such as muscle fiber composition and ribosomal content (during the early phase of resistance training).

The study will investigate the association between muscle fibre composition (type I vs type II muscle fiber proportions) / ribosomal content in m. vastus lateralis and the effects of 10 weeks of resistance training on endurance performance in 52 elite cyclists. Half the participants will perform resistance training in addition to their habitual endurance training routines, the other half will perform endurance training-only. Muscle biopsies will be sampled from m. vastus lateralis before and after the first two weeks of the intervention. For muscle fiber composition, the hypothesis is that larger proportions of type II fibers will be associated with more pronounced benefits of resistance training. For ribosomal content, the hypothesis is that higher rRNA content at baseline and larger increases in rRNA content during the initial part of the intervention will be associated with more pronounced benefits of resistance training. No changes are expected in the non-resistance training control group.

Study Design

Study Type:
Interventional
Actual Enrollment :
25 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Masking Description:
Participants/investigators will be blinded to muscle biological charateristics until after clean-up of main outcome variables. Participants/investigators will be aware of intervention arm affiliation.
Primary Purpose:
Treatment
Official Title:
Identifying Molecular Determinants for the Efficacy of Resistance Training for Improving Endurance Performance in Elite Cyclists
Actual Study Start Date :
Nov 16, 2020
Actual Primary Completion Date :
Feb 26, 2021
Actual Study Completion Date :
Feb 26, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Resistance training added to endurance training

Participants (elite cyclists) will conduct heavy-load resistance training twice a week in addition to their habitual endurance training for ten weeks

Behavioral: Resistance training
Resistance training sessions twice a week for ten weeks
Other Names:
  • Heavy-load strength training
  • Behavioral: Endurance training (habitual)
    Endurance training for ten weeks (habitual routines)

    Other: Endurance training

    Participants (elite cyclists) will conduct habitual endurance training-only for ten weeks

    Behavioral: Endurance training (habitual)
    Endurance training for ten weeks (habitual routines)

    Outcome Measures

    Primary Outcome Measures

    1. Performance during a 40-minute all-out cycling test [Changes from before the intervention to immediately after the intervention]

      Mean power output measured during a 40-minute all-out cycling test

    2. Performance during a 15-minute all-out cycling test [Changes from before the intervention to immediately after the intervention]

      Mean power output measured during a 15-minute all-out cycling test

    Secondary Outcome Measures

    1. Total RNA in muscle tissue (before intervention) [Before the intervention]

      Total RNA content in m. vastus lateralis (ug per mg tissue)

    2. Total RNA in muscle tissue (changes after two weeks) [Changes from before the intervention to immediately after the initial two weeks of resistance training]

      Total RNA content in m. vastus lateralis (ug per mg tissue)

    3. Muscle fiber proportions (before intervention) [Before the intervention]

      Muscle fiber proportions in m. vastus lateralis measured using immunohistochemistry

    4. Muscle fiber proportions (changes after two weeks) [Changes from before the intervention to immediately after the initial two weeks of resistance training]

      Muscle fiber proportions in m. vastus lateralis measured using immunohistochemistry

    5. Muscle fiber cross-sectional area (before intervention) [Before the intervention]

      Cross-sectional area of muscle fibres in m. vastus lateralis measured using immunohistochemistry

    6. Muscle fiber cross-sectional area (changes after two weeks) [Changes from before the intervention to immediately after the initial two weeks of resistance training]

      Cross-sectional area of muscle fibres in m. vastus lateralis measured using immunohistochemistry

    7. Myonuclear number (before intervention) [Before the intervention]

      Myonuclei per muscle fiber in m. vastus lateralis measured using immunohistochemistry

    8. Myonuclear number (changes after two weeks) [Changes from before the intervention to immediately after the initial two weeks of resistance training]

      Myonuclei per muscle fiber in m. vastus lateralis measured using immunohistochemistry

    9. rRNA expression (before intervention) [Before the intervention]

      rRNA abundances in m. vastus lateralis measured using qPCR

    10. rRNA expression (changes after two weeks) [Changes from before the intervention to immediately after the initial two weeks of resistance training]

      rRNA abundances in m. vastus lateralis measured using qPCR

    11. mRNA expression (before intervention) [Before the intervention]

      mRNA abundances in m. vastus lateralis measured using qPCR

    12. mRNA expression (changes after two weeks) [Changes from before the intervention to immediately after the initial two weeks of resistance training]

      mRNA abundances in m. vastus lateralis measured using qPCR

    13. Maximal concentric force production [Changes from before the intervention to immediately after the intervention]

      Maximal concentric force production measured using a seated leg press test

    14. Sprint performance [Changes from before the intervention to immediately after the intervention]

      Mean power output measured during a 10-second all-out cycling sprint

    15. Maximal oxygen consumption [Changes from before the intervention to immediately after the intervention]

      Maximal oxygen consumption measured during an incremental cycling exercise test to exhaustion

    16. Maximal aerobic power output [Changes from before the intervention to immediately after the intervention]

      Maximal aerobic power output measured as mean power output during the last minute of an incremental cycling exercise test to exhaustion

    17. Power output at lactate threshold [Changes from before the intervention to immediately after the intervention]

      Power output at 4 mmol blood lactate concentration measured during an incremental cycling exercise test (with 5 minute steps)

    18. Gross efficiency [Changes from before the intervention to immediately after the intervention]

      Contribution of total energy turnover to power output in the fresh and fatigued state

    19. Fractional utilization of VO2max (incremental test) [Changes from before the intervention to immediately after the intervention]

      Fractional utilization of VO2max measured at 4 mmol blood lactate concentrations measured during an incremental cycling exercise test (with 5 minute steps)

    20. Fractional utilization of VO2max (15-minute performance test) [Changes from before the intervention to immediately after the intervention]

      Fractional utilization of VO2max measured during a 15-minute performance test

    21. Hemoglobin mass [Changes from before the intervention to immediately after the intervention]

      Hemoglobin mass measured using CO rebreathing (g)

    22. Blood volume [Changes from before the intervention to immediately after the intervention]

      Blood volume measured using CO rebreathing

    23. Plasma volume [Changes from before the intervention to immediately after the intervention]

      Plasma volume measured using CO rebreathing

    24. Red blood cell volume [Changes from before the intervention to immediately after the intervention]

      Red blood cell volume measured using CO rebreathing

    25. Hematocrit [Changes from before the intervention to immediately after the intervention]

      Hematocrit measured using centrifugation

    Other Outcome Measures

    1. Endurance training volume [Throughout study completion (daily), an average of ten weeks]

      Self-reported endurance training volume measured as time-spent in different exercise intensity zones

    2. Resistance training volume [Throughout study completion (daily), an average of ten weeks]

      Self-reported resistance training volume measured as load x repetitions

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion criteria:
    • VO2max > 65 ml/kg/min (male participants)

    • VO2max > 50 ml/kg/min (female participants)

    • 7 hours of endurance training per week for the 6 months leading up to the study

    Exclusion criteria:
    • having conducted regular resistance training for the last 6 months leading up to the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Inland Norway University of Applied Sciences Lillehammer Inland Norway Norway 2613

    Sponsors and Collaborators

    • Inland Norway University of Applied Sciences

    Investigators

    • Study Chair: Anne S Lofthus, Research Administrator

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Inland Norway University of Applied Sciences
    ClinicalTrials.gov Identifier:
    NCT04637178
    Other Study ID Numbers:
    • Trainome 2020#025-2
    First Posted:
    Nov 19, 2020
    Last Update Posted:
    Mar 1, 2021
    Last Verified:
    Nov 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Inland Norway University of Applied Sciences

    Study Results

    No Results Posted as of Mar 1, 2021